
Opinion|Videos|May 6, 2024
Apolipoprotein E4 in Alzheimer’s Disease
Sharon Cohen, MD, and Marwan Sabbagh, MD, differentiate between the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD), and highlight known risk factors, including the contribution of ApoE gene polymorphism and copy numbers.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following question(s):
- How are different stages of Alzheimer’s disease (AD; preclinical AD, prodromal AD, and AD with dementia) defined?
- What are known risk factors for Alzheimer's disease?
- Contribution of ApoE gene polymorphism and copy numbers
- When do patients with Alzheimer’s typically present to the clinic?
- What are known risk factors for Alzheimer's disease?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Tolebrutinib Falls Short in Phase 3 PERSEUS Study, Forcing Decision to Redact Regulatory Submission
2
Exploring the Integration of AI into the field of Epilepsy: Balu Krishnan, MD
3
Beyond Dravet and LGS: Elizabeth Thiele, MD, PhD, on New Data for Epidiolex in DEEs
4
What the First Intrathecal Gene Therapy Means for SMA Clinicians and Researchers
5





















